

Association of highly active antiretroviral therapy coverage with  
yearly new HIV diagnoses in British Columbia, Canada:

Lancet, The

376, 532-539

DOI: [10.1016/S0140-6736\(10\)60936-1](https://doi.org/10.1016/S0140-6736(10)60936-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Reply to "Evidence is still required for treatment as prevention for riskier routes of HIV transmission". <i>Aids</i> , 2010, 24, 2892-2893.	2.2	1
2	Evidence is still required for treatment as prevention for riskier routes of HIV transmission. <i>Aids</i> , 2010, 24, 2891-2892.	2.2	9
3	Antiretroviral Therapy: A Promising HIV Prevention Strategy?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, S116-S121.	2.1	23
4	Antiretroviral Therapy Use Among HIV-Infected Men Who Have Sex With Men Attending a Sexually Transmitted Diseases Clinic. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 524-527.	2.1	6
5	Developing Canada's Research Base for Harm Reduction and Health Equity Approaches to HIV Prevention and Treatment. <i>Canadian Journal of Public Health</i> , 2010, 101, 442-444.	2.3	1
6	AIDS Funds: Benefits. <i>Science</i> , 2010, 330, 175-176.	12.6	6
7	Prevention and Treatment of HIV/AIDS Among Drug-Using Populations: A Global Perspective. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, S1-S4.	2.1	7
8	A Way Forward: The National HIV/AIDS Strategy and Reducing HIV Incidence in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, S144-S147.	2.1	79
9	Is HAART modifying the HIV epidemic?. <i>Lancet, The</i> , 2010, 376, 492-493.	13.7	14
10	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. <i>Lancet, The</i> , 2010, 376, 1838-1845.	13.7	1,098
11	Is antiretroviral therapy modifying the HIV epidemic?. <i>Lancet, The</i> , 2010, 376, 1824.	13.7	9
12	Is antiretroviral therapy modifying the HIV epidemic?. <i>Lancet, The</i> , 2010, 376, 1824-1825.	13.7	15
13	Scale-up of diagnostics for multidrug resistant tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 656-658.	9.1	10
14	Reduction of HIV incidence in men who have sex with men. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 655-656.	9.1	4
15	Advancing HIV Prevention Among Multiethnic Vulnerable Youths: Ethnoracial and Gender Differences. <i>Journal of HIV/AIDS and Social Services</i> , 2011, 10, 311-324.	0.7	0
16	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 493-505.	27.0	6,046
17	Development of Antiretroviral Drug Resistance. <i>New England Journal of Medicine</i> , 2011, 365, 637-646.	27.0	187
18	HIV treatment for prevention. <i>Journal of the International AIDS Society</i> , 2011, 14, 28-28.	3.0	30

#	ARTICLE	IF	CITATIONS
19	Potential role of safer injection facilities in reducing HIV and Hepatitis C infections and overdose mortality in the United States. <i>Drug and Alcohol Dependence</i> , 2011, 118, 100-110.	3.2	40
20	Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV. <i>Life Sciences</i> , 2011, 88, 940-947.	4.3	101
21	HIV-2 down, HIV-1 to go? Understanding the possibilities of treatment as prevention. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 260-261.	9.1	5
22	Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 516-524.	9.1	234
23	Treatment 2.0: catalysing the next phase of scale-up. <i>Lancet</i> , The, 2011, 378, 209-211.	13.7	39
24	Treatment as preventionâ€”a double hat-trick. <i>Lancet</i> , The, 2011, 378, 208-209.	13.7	116
25	Missed Opportunities for HIV Testing and Late-Stage Diagnosis among HIV-Infected Patients in Uganda. <i>PLoS ONE</i> , 2011, 6, e21794.	2.5	52
26	Social marketing interventions to increase HIV/STI testing uptake among men who have sex with men and male-to-female transgender women. <i>The Cochrane Library</i> , 2011, , CD009337.	2.8	63
27	Probiotics: The Potential for a Live Microbicide to Prevent HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e98-e101.	2.1	4
28	Retention on Antiretroviral Therapy in National Programs in Low-Income and Middle-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e102-e103.	2.1	0
29	Multiple Sexual Partnerships Among Poor Urban Dwellers in Kampala, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 153-156.	2.1	23
30	Kaposi Sarcoma-Associated Herpesvirus Serum DNA and Antibodies Not Associated With Subsequent Non-Hodgkin Lymphoma Risk: Erratum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e103.	2.1	0
31	Estimating the HIV incidence rate: recent and future developments. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 102-107.	3.8	44
32	MSM: resurgent epidemics. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 326-332.	3.8	24
33	MAYER AND VENKATESH RESPOND. <i>American Journal of Public Health</i> , 2011, 101, 199-200.	2.7	1
34	BATHING AS A POTENTIAL TARGET FOR DISABILITY REDUCTION IN THE OLDEST OLD. <i>American Journal of Public Health</i> , 2011, 101, 200-201.	2.7	2
35	Treatment-centred prevention. <i>Aids</i> , 2011, 25, 1435-1437.	2.2	1
36	Is Tenofovir-Related Renal Toxicity Incompletely Reversible?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e95.	2.1	8

#	ARTICLE	IF	CITATIONS
37	Efficiencies in AIDS Programming. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 229-232.	2.1	2
38	Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. <i>Aids</i> , 2011, 25, 1939-1949.	2.2	47
39	HIV Treatment as Prevention: In the Real World the Details Matter. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e101-e102.	2.1	6
40	Retention Among Adults Initiating Antiretroviral Therapy in South Africa: 2002-2007. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e102.	2.1	0
41	Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000-2009. <i>Aids</i> , 2011, 25, 977-988.	2.2	26
42	Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. <i>Aids</i> , 2011, 25, 1113-1118.	2.2	44
43	Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. <i>Aids</i> , 2011, 25, 2019-2026.	2.2	35
44	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011, 25, 1437-1439.	2.2	23
45	Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. <i>Aids</i> , 2011, 25, 291-293.	2.2	142
46	Responding to the National HIV/AIDS Strategy-Setting the Research Agenda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 175-180.	2.1	18
47	Bacterial translocation. <i>Aids</i> , 2011, 25, 1439-1441.	2.2	3
48	Early antiretroviral therapy reduced HIV-1 transmission in serodiscordant couples. <i>Annals of Internal Medicine</i> , 2011, 155, JC6.	3.9	0
49	If We Can't Get What We Want, Can We Get What We Need? Optimizing Use of Antiretroviral Therapy in the Current Era. <i>Annals of Internal Medicine</i> , 2011, 154, 563.	3.9	2
50	HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. <i>Journal of Internal Medicine</i> , 2011, 270, 532-549.	6.0	14
52	Trends in detectable viral load by calendar year in the Australian HIV observational database. <i>Journal of the International AIDS Society</i> , 2011, 14, 10-10.	3.0	28
53	Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 591-610.	2.8	1
54	Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy. <i>Current HIV/AIDS Reports</i> , 2011, 8, 85-93.	3.1	21
55	HIV Counseling and Testing for Household Members of HIV-Infected Individuals in Africa: Should Prevention Programs Focus on Home-Based Rather than Clinic-Based Outreach?. <i>Current HIV/AIDS Reports</i> , 2011, 8, 75-77.	3.1	1

#	ARTICLE	IF	CITATIONS
56	Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?. <i>Current Infectious Disease Reports</i> , 2011, 13, 68-74.	3.0	5
57	Combination therapy: the next opportunity and challenge of medicine. <i>Journal of Translational Medicine</i> , 2011, 9, 115.	4.4	71
58	Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study. <i>AIDS Research and Therapy</i> , 2011, 8, 31.	1.7	1
59	Immune-mediated attenuation of HIV-1. <i>Future Virology</i> , 2011, 6, 917-928.	1.8	14
60	Combination antiretroviral therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 995-998.	1.8	7
61	Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV. <i>Current HIV Research</i> , 2011, 9, 367-382.	0.5	51
62	Cost-Effectiveness of Antiretroviral Therapy for Prevention. <i>Current HIV Research</i> , 2011, 9, 405-415.	0.5	23
63	Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts. <i>Current HIV Research</i> , 2011, 9, 446-469.	0.5	89
64	Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis. <i>Current HIV Research</i> , 2011, 9, 355-366.	0.5	6
65	Why HIV/AIDS should be treated as exceptional: arguments from sub-Saharan Africa and Eastern Europe. <i>African Journal of AIDS Research</i> , 2011, 10, 345-356.	0.9	5
66	Reply to Wilson et al. <i>Clinical Infectious Diseases</i> , 2011, 53, 612-613.	5.8	1
67	The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. <i>Health Education Research</i> , 2011, 26, 381-392.	1.9	33
68	Is the recall of men who have sex with men (MSM) diagnosed as having bacterial sexually transmitted infections (STIs) for re-screening a feasible and effective strategy?. <i>Sexually Transmitted Infections</i> , 2011, 87, 577-582.	1.9	22
69	Recent Decline in the Incidence of Human Immunodeficiency Virus Infection Among California Men Who Have Sex With Men. <i>American Journal of Epidemiology</i> , 2011, 174, 203-210.	3.4	20
70	Antiretroviral Therapy: Now "It Just Works". <i>Clinical Infectious Diseases</i> , 2011, 53, 605-608.	5.8	2
71	ARVs as HIV Prevention: A Tough Road to Wide Impact. <i>Science</i> , 2011, 334, 1645-1646.	12.6	30
72	Using HIV Diagnostic Data to Estimate HIV Incidence: Method and Simulation. <i>Statistical Communications in Infectious Diseases</i> , 2011, 3, .	0.2	7
73	Remedicalizing an epidemic. <i>Aids</i> , 2011, 25, 1435.	2.2	13

#	ARTICLE	IF	CITATIONS
74	Implications of the Henan Province Report on the Treatment as Prevention Debate. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e101.	2.1	7
75	Clinical Impact and Cost of Laboratory Monitoring Need Review Even in Resource-Rich Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e97-e98.	2.1	8
76	The 30-Year War on AIDS: Have We Reached the Tipping Point?. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1089-1093.	1.7	0
77	eGFR Slope and Tenofovir Nephrotoxicity. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e95-e96.	2.1	0
78	The Effect of Expanded Antiretroviral Treatment Strategies on the HIV Epidemic Among Men Who Have Sex With Men in San Francisco. <i>Clinical Infectious Diseases</i> , 2011, 52, 1046-1049.	5.8	81
79	Detrimental Effect of Atazanavir Plasma Concentrations on Total Serum Bilirubin Levels in the Presence of UGT1A1 Polymorphisms. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e96-e97.	2.1	5
80	Abacavir and lamivudine for the treatment of human immunodeficiency virus. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2129-2138.	1.8	3
81	A Community-Based Study of Barriers to HIV Care Initiation. <i>AIDS Patient Care and STDs</i> , 2011, 25, 601-609.	2.5	46
82	Introduction: Linkage, Engagement, and Retention in HIV Care: Essential for Optimal Individual- and Community-Level Outcomes in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 52, S205-S207.	5.8	80
83	Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. <i>PLoS Medicine</i> , 2011, 8, e1001123.	8.4	130
84	Two Sides to the HIV Prevention Coin: Efficacy and Effectiveness. <i>AIDS Education and Prevention</i> , 2011, 23, 393-396.	1.1	16
85	Human Leukocyte Antigen (HLA) Class I Down-Regulation by Human Immunodeficiency Virus Type 1 Negative Factor (HIV-1 Nef): What Might We Learn From Natural Sequence Variants?. <i>Viruses</i> , 2012, 4, 1711-1730.	3.3	22
86	Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-8.	0.7	8
87	HIV Treatment as Prevention: The Utility and Limitations of Ecological Observation. <i>PLoS Medicine</i> , 2012, 9, e1001260.	8.4	56
88	HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention. <i>PLoS Medicine</i> , 2012, 9, e1001231.	8.4	117
89	HIV Treatment as Prevention: Modelling the Cost of Antiretroviral Treatment—State of the Art and Future Directions. <i>PLoS Medicine</i> , 2012, 9, e1001247.	8.4	56
90	Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001270.	8.4	298
91	The perilous state of independent randomized clinical trials and related applied research in Canada. <i>Cmaj</i> , 2012, 184, 1997-2002.	2.0	7

#	ARTICLE	IF	CITATIONS
92	Mapping HIV community viral load: space, power and the government of bodies. <i>Critical Public Health</i> , 2012, 22, 471-483.	2.4	19
93	HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. <i>PLoS Medicine</i> , 2012, 9, e1001259.	8.4	64
94	Reaping the prevention benefits of highly active antiretroviral treatment. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 111-116.	3.8	35
95	HIV and viral hepatitis C coinfection in people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 339-344.	3.8	20
96	Antiretrovirals and safer conception for HIV-serodiscordant couples. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 569-578.	3.8	122
97	HIV treatment as prevention among injection drug users. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 151-156.	3.8	59
98	Optimizing the engagement of care cascade. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 579-586.	3.8	93
99	HIV treatment as prevention and HPTN 052. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 99-105.	3.8	230
100	Prevention of HIV-1 infection with early antiretroviral therapy. <i>Journal of Family Planning and Reproductive Health Care</i> , 2012, 38, 193-193.	0.8	4
101	Untested and undiagnosed: barriers to HIV testing among men who have sex with men, Beijing, China. <i>Sexually Transmitted Infections</i> , 2012, 88, 187-193.	1.9	62
102	Tracking linkage to HIV care for former prisoners. <i>Virulence</i> , 2012, 3, 319-324.	4.4	18
103	Therapeutic vaccines against HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 569-581.	3.3	55
104	Operationalizing Treatment as Prevention in Los Angeles County: Antiretroviral Therapy Use and Factors Associated with Unsuppressed Viral Load in the Ryan White System of Care. <i>AIDS Patient Care and STDs</i> , 2012, 26, 463-470.	2.5	18
105	Preferences for Rapid Point-of-Care HIV Testing in Primary Care. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 157-163.	1.2	6
106	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. <i>Aids</i> , 2012, 26, 1231-1241.	2.2	132
107	Effect of HSV-2 Suppressive Therapy on Genital Tract HIV-1 RNA Shedding among Women on HAART: A Pilot Randomized Controlled Trial. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2012, 2012, 1-7.	1.5	1
108	Treatment as prevention. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 157-163.	3.8	19
110	Consideration of Postpartum Management in HIV-Positive Haitian Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 636-643.	2.1	12

#	ARTICLE	IF	CITATIONS
111	Retention in Care of Adults and Adolescents Living With HIV in 13 US Areas. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 77-82.	2.1	158
112	Lessons learned from the first wave of aging with HIV. <i>Aids</i> , 2012, 26, S11-S18.	2.2	39
113	Is Total Community Viral Load a Robust Predictive Marker of the Efficacy of the TasP Strategy?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 400-402.	2.1	22
114	Operational research and HIV policy and guidelines: Lessons from a study of patients lost to follow-up from a public antiretroviral treatment program in Cameroon. <i>Journal of Public Health Policy</i> , 2012, 33, 462-477.	2.0	5
115	Paying for Prevention: Challenges to Health Insurance Coverage for Biomedical HIV Prevention in the United States. <i>American Journal of Law and Medicine</i> , 2012, 38, 607-666.	0.2	10
116	The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. <i>Aids</i> , 2012, 26, S19-S30.	2.2	136
117	Beyond the Distinction Between Biomedical and Social Dimensions of HIV Prevention Through the Lens of a Social Public Health. <i>American Journal of Public Health</i> , 2012, 102, 789-799.	2.7	152
118	Community-based multi-disease prevention campaigns for controlling human immunodeficiency virus-associated tuberculosis [Perspectives]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 430-436.	1.2	6
119	Antiviral agents and HIV prevention. <i>Aids</i> , 2012, 26, 1585-1598.	2.2	89
120	Effective HIV prevention: the indispensable role of social science. <i>Journal of the International AIDS Society</i> , 2012, 15, 17357.	3.0	67
121	Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. <i>Aids</i> , 2012, 26, 77-86.	2.2	70
122	The evolving epidemiology of HIV/AIDS. <i>Aids</i> , 2012, 26, 1205-1213.	2.2	164
123	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. <i>Aids</i> , 2012, 26, 2079-2086.	2.2	47
124	Stable Incidence of HIV Diagnoses Among Danish MSM Despite Increased Engagement in Unsafe Sex. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 106-111.	2.1	30
125	Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, e65-e69.	2.1	21
126	Does ART prevent HIV transmission among MSM?. <i>Aids</i> , 2012, 26, 2267-2273.	2.2	56
127	Living conditions, quality of life, adherence and treatment outcome in Greenlandic HIV patients. <i>International Journal of Circumpolar Health</i> , 2012, 71, 18639.	1.2	9
128	Putting risk compensation to rest. <i>Aids</i> , 2012, 26, 2405-2407.	2.2	3



#	ARTICLE	IF	CITATIONS
129	HIV Sexual Networks: The Montreal Experience. <i>Statistical Communications in Infectious Diseases</i> , 2012, 4, .	0.2	6
130	Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel. <i>Annals of Internal Medicine</i> , 2012, 156, 817.	3.9	519
131	Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. <i>Current Opinion in Virology</i> , 2012, 2, 599-605.	5.4	8
132	A harm reduction paradox: Comparing China's policies on needle and syringe exchange and methadone maintenance. <i>International Journal of Drug Policy</i> , 2012, 23, 327-332.	3.3	16
133	A typology of structural approaches to HIV prevention: A commentary on Roberts and Matthews. <i>Social Science and Medicine</i> , 2012, 75, 1562-1567.	3.8	17
135	HIV Treatment Adherence, Patient Health Literacy, and Health Care Providerâ€™Patient Communication. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 128-133.	1.2	45
136	Major differences in assisted reproductive treatments offered to HIV-1 infected patients in the Nordic countries. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 402-404.	1.5	4
137	Empowering HIV testing as a prevention tool: Targeting interventions for high-risk men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1039-1045.	1.2	14
138	Discussions of viral load in negotiating sexual episodes with primary and casual partners among men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 1052-1055.	1.2	20
140	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. <i>New England Journal of Medicine</i> , 2012, 367, 399-410.	27.0	2,665
142	Overview of antiretroviral therapy. , 2012, , 133-153.		0
143	A Systematic Review of Antiretroviral Adherence Interventions for HIV-Infected People Who Use Drugs. <i>Current HIV/AIDS Reports</i> , 2012, 9, 287-312.	3.1	89
144	Deadly Public Policy: What the Future Could Hold for the HIV Epidemic among Injection Drug Users in Vancouver. <i>Current HIV/AIDS Reports</i> , 2012, 9, 394-400.	3.1	14
145	The World Must Build On Three Decades Of Scientific Advances To Enable A New Generation To Live Free Of HIV/AIDS. <i>Health Affairs</i> , 2012, 31, 1529-1536.	5.2	14
146	Home-based HIV counseling and testing: Client experiences and perceptions in Eastern Uganda. <i>BMC Public Health</i> , 2012, 12, 966.	2.9	39
147	A Complex Systems Approach to Evaluate HIV Prevention in Metropolitan Areas: Preliminary Implications for Combination Intervention Strategies. <i>PLoS ONE</i> , 2012, 7, e44833.	2.5	42
148	Screening for HIV: Systematic Review to Update the 2005 U.S. Preventive Services Task Force Recommendation. <i>Annals of Internal Medicine</i> , 2012, 157, 706.	3.9	32
149	Increased HIV testing in men who have sex with men. <i>BMJ: British Medical Journal</i> , 2012, 344, e501-e501.	2.3	4

#	ARTICLE	IF	CITATIONS
150	HIV Testing and Management: Findings from a National Sample of Asian/Pacific Islander Men Who Have Sex with Men. <i>Public Health Reports</i> , 2012, 127, 186-194.	2.5	20
152	Eleventh International Congress on Drug Therapy in HIV Infection. <i>Journal of the International AIDS Society</i> , 2012, 15, 18447.	3.0	0
153	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. <i>Annals of Internal Medicine</i> , 2012, 157, 325.	3.9	106
154	Time trends and correlates of late presentation for HIV care in Northern Greece during the decade 2000 to 2010. <i>Journal of the International AIDS Society</i> , 2012, 15, 17395.	3.0	14
155	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402.	7.4	1,239
156	Conduct disorder and adult psychiatric diagnoses: Associations and gender differences in the U.S. adult population. <i>Journal of Psychiatric Research</i> , 2012, 46, 323-330.	3.1	38
157	Late presentation of HIV despite earlier opportunities for detection, experience from an Irish Tertiary Referral Institution. <i>Irish Journal of Medical Science</i> , 2013, 182, 389-394.	1.5	9
158	Antiretroviral Therapy for Prevention Is a Combination Strategy. <i>Current HIV/AIDS Reports</i> , 2013, 10, 152-158.	3.1	32
159	Combination Prevention: New Hope for Stopping the Epidemic. <i>Current HIV/AIDS Reports</i> , 2013, 10, 169-186.	3.1	68
160	Sex with Sex Workers among Latino Day Laborers in Suburban Maryland. <i>Archives of Sexual Behavior</i> , 2013, 42, 835-849.	1.9	6
161	Treatment as prevention for HIV in China. <i>Lancet, The</i> , 2013, 382, 1159-1161.	13.7	6
163	HIV treatment as prevention: The key to an AIDS-free generation. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S95-S101.	1.9	40
164	Chimeric Cyanovirin-MPER Recombinantly Engineered Proteins Cause Cell-Free Virolysis of HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4743-4750.	3.2	20
165	Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. <i>Harm Reduction Journal</i> , 2013, 10, 13.	3.2	49
166	Interventions to Promote Linkage to and Utilization of HIV Medical Care Among HIV-diagnosed Persons: A Qualitative Systematic Review, 1996â€“2011. <i>AIDS and Behavior</i> , 2013, 17, 1941-1962.	2.7	77
167	Aggregate Versus Day Level Association Between Methamphetamine Use and HIV Medication Non-adherence Among Gay and Bisexual Men. <i>AIDS and Behavior</i> , 2013, 17, 1478-1487.	2.7	42
168	Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. <i>BMC Infectious Diseases</i> , 2013, 13, 565.	2.9	27
169	Non-natural Peptide Triazole Antagonists of HIV-1 Envelope gp120. <i>ChemMedChem</i> , 2013, 8, 322-328.	3.2	14

#	ARTICLE	IF	CITATIONS
170	The emerging HIV epidemic among men who have sex with men in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 369-371.	1.7	8
171	Time for universality to reduce inequity. <i>Lancet, The</i> , 2013, 382, 1161-1163.	13.7	1
172	Community viral load as a measure for assessment of HIV treatment as prevention. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 459-464.	9.1	102
173	HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 313-318.	9.1	100
174	Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for "Test and Treat"™ Prevention Strategy. <i>AIDS Patient Care and STDs</i> , 2013, 27, 681-691.	2.5	23
175	Antiretroviral therapy in men who have sex with men. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 654-655.	9.1	1
176	Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. <i>Lancet, The</i> , 2013, 382, 1515-1524.	13.7	202
177	People Who Inject Drugs, HIV Risk, and HIV Testing Uptake in Sub-Saharan Africa. <i>Journal of the Association of Nurses in AIDS Care</i> , 2013, 24, e35-e44.	1.0	43
178	Antiretroviral therapy for prevention of HIV transmission: Potential role for people who inject drugs in Central Asia. <i>Drug and Alcohol Dependence</i> , 2013, 132, S65-S70.	3.2	8
179	HIV and people who use drugs in central Asia: Confronting the perfect storm. <i>Drug and Alcohol Dependence</i> , 2013, 132, S2-S6.	3.2	30
180	Human Immunodeficiency Virus Infection. , 2013, , 217-247.		0
181	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. <i>Journal of Infectious Diseases</i> , 2013, 207, S101-S106.	4.0	21
182	<sc>HIV</sc> treatment as prevention among men who have sex with men in the <sc>UK</sc>: is transmission controlled by universal access to <sc>HIV</sc> treatment and care?. <i>HIV Medicine</i> , 2013, 14, 563-570.	2.2	37
183	Evaluation of the accuracy and ease of use of a rapid HIV-1 Antibody Test performed by untrained operators at the point of care. <i>Journal of Clinical Virology</i> , 2013, 58, e65-e69.	3.1	18
184	Global Policy Review of Antiretroviral Therapy Eligibility Criteria for Treatment and Prevention of HIV and Tuberculosis in Adults, Pregnant Women, and Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, e87-e97.	2.1	29
185	Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. <i>Aids</i> , 2013, 27, 1159-1165.	2.2	23
186	Targeting screening and social marketing to increase detection of acute HIV infection in men who have sex with men in Vancouver, British Columbia. <i>Aids</i> , 2013, 27, 2649-2654.	2.2	26
187	Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. <i>The Cochrane Library</i> , 2013, , CD009153.	2.8	97

#	ARTICLE	IF	CITATIONS
188	Commentary: HIV testing in low- and middle-income countries: An urgent need for scaling up. <i>Journal of Public Health Policy</i> , 2013, 34, 17-21.	2.0	6
189	Can the "Seek, Test, Treat, and Retain" Strategy be Effective in France?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, e119-e121.	2.1	3
190	Understanding the Disparity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 289-298.	2.1	45
191	Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. <i>Aids</i> , 2013, 27, 2559-2566.	2.2	90
192	The Effect of Churn on "Community Viral Load" in a Well-Defined Regional Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 190-196.	2.1	12
193	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. <i>American Journal of Psychiatry</i> , 2013, 170, 1413-1422.	7.2	82
194	HIV-1 Genetic Variability and Clinical Implications. , 2013, 2013, 1-20.		115
195	Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. <i>PLoS Medicine</i> , 2013, 10, e1001534.	8.4	124
196	Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 593-599.	1.2	0
197	HIV infection among people who inject drugs: The challenge of racial/ethnic disparities.. <i>American Psychologist</i> , 2013, 68, 274-285.	4.2	14
198	"Test-and-Treat" Strategy for Control of HIV and AIDS Can Lead to a Decrease, Not an Increase, of Multidrug-Resistant Viruses. <i>Clinical Infectious Diseases</i> , 2013, 57, 478-479.	5.8	3
199	Fifteen million people on antiretroviral treatment by 2015. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 41-49.	3.8	33
200	High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa. <i>Science</i> , 2013, 339, 966-971.	12.6	700
201	Universal Antiretroviral Therapy for HIV Infection: Should US Treatment Guidelines Be Applied to Resource-Limited Settings?. <i>Clinical Infectious Diseases</i> , 2013, 57, 884-887.	5.8	26
202	Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe. <i>Journal of Infectious Diseases</i> , 2013, 207, 1216-1220.	4.0	53
203	Assessment of Population-Based HIV RNA Levels in a Rural East African Setting Using a Fingerprick-Based Blood Collection Method. <i>Clinical Infectious Diseases</i> , 2013, 56, 598-605.	5.8	33
204	Prospects of elimination of HIV with test-and-treat strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15538-15543.	7.1	51
205	Controlling the HIV Epidemic with Antiretrovirals. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 208-216.	1.5	36

#	ARTICLE	IF	CITATIONS
206	Partner violence and health among HIV-infected jail detainees. <i>International Journal of Prisoner Health</i> , 2013, 9, 124-141.	0.9	23
207	Recent trends in HIV prevalence in a remote setting of southern India: Insights into arranging HIV control policies. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 838-843.	1.2	1
208	Potential Impact of the US President's Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries. <i>Journal of Infectious Diseases</i> , 2013, 208, 2075-2084.	4.0	7
209	Persistent Genital Tract HIV-1 RNA Shedding After Change in Treatment Regimens in Antiretroviral-Experienced Women with Detectable Plasma Viral Load. <i>Journal of Women's Health</i> , 2013, 22, 330-338.	3.3	8
210	Health Care and HIV Testing Experiences Among Black Men in the South: Implications for "Seek, Test, Treat, and Retain" HIV Prevention Strategies. <i>AIDS Patient Care and STDs</i> , 2013, 27, 123-133.	2.5	39
211	HIV Medication Adherence and HIV Symptom Severity: The Roles of Sleep Quality and Memory. <i>AIDS Patient Care and STDs</i> , 2013, 27, 544-552.	2.5	45
212	Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions. <i>HIV Medicine</i> , 2013, 14, 581-582.	2.2	13
213	Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. <i>AIDS Patient Care and STDs</i> , 2013, 27, 155-162.	2.5	6
214	Shifting the Paradigm: Using HIV Surveillance Data as a Foundation for Improving HIV Care and Preventing HIV Infection. <i>Milbank Quarterly</i> , 2013, 91, 558-603.	4.4	79
215	CD4 T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. <i>Antiviral Therapy</i> , 2013, 19, 31-39.	1.0	11
216	HIV and hepatitis C virus test uptake at methadone clinics in Southern China: opportunities for expanding detection of bloodborne infections. <i>BMC Public Health</i> , 2013, 13, 899.	2.9	17
217	The Potential Impact of Expanding Antiretroviral Therapy and Combination Prevention in Vietnam. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e142-e149.	2.1	61
218	Disparities in community viral load among HIV-infected persons in New York city. <i>Aids</i> , 2013, 27, 2129-2139.	2.2	15
219	The 16th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 2013, 8, 331-333.	1.8	0
220	Phylogenetic inferences on HIV-1 transmission. <i>Aids</i> , 2013, 27, 1045-1057.	2.2	83
221	Future of Phylogeny in HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S248-S254.	2.1	34
222	Antiretroviral Therapy for Prevention of HIV and Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S200-S207.	2.1	10
223	Revisiting the Methodology of Measuring HIV Community Viral Load. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e82-e84.	2.1	12

#	ARTICLE	IF	CITATIONS
224	Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S221-S227.	2.1	39
225	Population dynamics of HIV-2 in rural West Africa. <i>Aids</i> , 2013, 27, 125-134.	2.2	32
226	Measuring the Unknown. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, e84-e86.	2.1	20
227	Community Viral Load and CD4 Count Distribution Among People Living With HIV in a South African Township. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 498-505.	2.1	41
229	Ten Year Trends in Community HIV Viral Load in Barbados: Implications for Treatment as Prevention. <i>PLoS ONE</i> , 2013, 8, e58590.	2.5	11
230	Changes in Sexual Behaviors among HIV-Infected Individuals after Their HIV Diagnosis in a Rural Prefecture of Eastern China. <i>PLoS ONE</i> , 2013, 8, e59575.	2.5	3
231	Willingness to Use the Oral Fluid HIV Rapid Test among Men Who Have Sex with Men in Beijing, China. <i>PLoS ONE</i> , 2013, 8, e64652.	2.5	22
232	Routine HIV Testing among Hospitalized Patients in Argentina. Is It Time for a Policy Change?. <i>PLoS ONE</i> , 2013, 8, e69517.	2.5	5
233	Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Rural Yunnan, China. <i>PLoS ONE</i> , 2013, 8, e77981.	2.5	48
234	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	2.5	1,111
235	Cardiovascular Risk Assessment: A Comparison of the Framingham, PROCAM, and DAD Equations in HIV-Infected Persons. <i>Scientific World Journal</i> , The, 2013, 2013, 1-9.	2.1	46
236	The Problem of Late ART Initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon?. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 359-383.	0.8	91
237	Cuerpos, virus y econom�as morales: la prueba del VIH. <i>Política Y Sociedad</i> , 2013, 50, .	0.2	1
238	Thai Dental Practitioners' Knowledge and Attitudes Regarding Patients with HIV. <i>Journal of Dental Education</i> , 2013, 77, 1202-1208.	1.2	8
239	HIV medication adherence, substance use, sexual risk behaviors and psychological distress among younger black men who have sex with men and transgender women: Preliminary findings. <i>Journal of Nursing Education and Practice</i> , 2014, 4, .	0.2	0
240	'Getting to zero' in Asia and the Pacific through more strategic use of antiretrovirals for HIV prevention. <i>Sexual Health</i> , 2014, 11, 107.	0.9	4
241	High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. <i>Sexual Health</i> , 2014, 11, 291.	0.9	5
242	High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. <i>PLoS ONE</i> , 2014, 9, e115277.	2.5	62

#	ARTICLE	IF	CITATIONS
243	Predicting the population impact of increased HIV testing and treatment in Australia. <i>Sexual Health</i> , 2014, 11, 146.	0.9	22
244	HIV Treatment as Prevention: Contradictory Perspectives from Dynamic Mathematical Models. <i>Scientific World Journal</i> , The, 2014, 2014, 1-9.	2.1	2
245	Time since last negative HIV test among men who have sex with men and people who use injection drugs in British Columbia, 2006-2011. <i>Canadian Journal of Public Health</i> , 2014, 105, e63-e68.	2.3	7
246	Can we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA Panel. <i>Journal of the International AIDS Society</i> , 2014, 17, 19766.	3.0	0
247	Tuberculosis in HIV-infected persons in British Columbia during the HAART era. <i>Canadian Journal of Public Health</i> , 2014, 105, e258-e262.	2.3	6
248	Correlates of HIV infection and being unaware of HIV status among soon-to-be released Ukrainian prisoners. <i>Journal of the International AIDS Society</i> , 2014, 17, 19005.	3.0	13
251	Advancing population and public health ethics regarding HIV testing: a scoping review. <i>Critical Public Health</i> , 2014, 24, 283-295.	2.4	14
252	Modeling the Implementation of Universal Coverage for HIV Treatment as Prevention and its Impact on the HIV Epidemic. <i>Current HIV/AIDS Reports</i> , 2014, 11, 459-467.	3.1	16
253	Reaching the Unreached: Treatment as Prevention as a Workable Strategy to Mitigate HIV and Its Consequences in High-Risk Groups. <i>Current HIV/AIDS Reports</i> , 2014, 11, 505-512.	3.1	13
254	The effect of history of injection drug use and alcoholism on HIV disease progression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 123-129.	1.2	16
255	HIV-1 Drug Resistance in Preexposure Prophylaxis Trials. , 2014, , 1-18.		0
256	Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1003-1011.	5.8	50
257	The Prospect Of A Generation Free Of HIV May Be Within Reach If The Right Policy Decisions Are Made. <i>Health Affairs</i> , 2014, 33, 428-433.	5.2	10
258	An HIV Epidemic Model Based on Viral Load Dynamics: Value in Assessing Empirical Trends in HIV Virulence and Community Viral Load. <i>PLoS Computational Biology</i> , 2014, 10, e1003673.	3.2	27
259	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. <i>PLoS Genetics</i> , 2014, 10, e1004295.	3.5	45
260	Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP) Tj ETQq1 1 0.784314 rgBT /Overlock 1.9 56		
261	HIV Prevention Services and Testing Utilization Behaviors among Men Who Have Sex with Men at Elevated Risk for HIV in Chongqing, China. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	14
262	Seek, test, treat and retain for hepatitis C in the United States criminal justice system. <i>International Journal of Prisoner Health</i> , 2014, 10, 164-171.	0.9	17



#	ARTICLE	IF	CITATIONS
264	Antiretrovirals for HIV prevention: when should they be recommended?. Expert Review of Anti-Infective Therapy, 2014, 12, 431-445.	4.4	1
265	Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "see, test, treat, and retain" strategy?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1058-1069.	1.2	2
266	Late HIV Diagnosis: Differences by Rural/Urban Residence, Florida, 2007-2011. AIDS Patient Care and STDs, 2014, 28, 188-197.	2.5	59
267	Correlates of Having Never Been HIV Tested among Entrants to Substance Abuse Treatment Clinics: Empiric Findings from Real-World New England Settings. Journal of Psychoactive Drugs, 2014, 46, 208-214.	1.7	6
268	Treatment as Prevention "Where Next?. Current HIV/AIDS Reports, 2014, 11, 496-504.	3.1	20
269	Antiretroviral Drug Costs and Prescription Patterns in British Columbia, Canada. Medical Care, 2014, 52, 362-369.	2.4	8
270	Stimulant Use and Progression to AIDS or Mortality After the Initiation of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 508-513.	2.1	53
271	Depression During Pregnancy and the Postpartum Among HIV-Infected Women on Antiretroviral Therapy in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S179-S187.	2.1	53
272	Process Monitoring of an HIV Treatment as Prevention Program in British Columbia, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e94-e109.	2.1	16
273	HIV viral load levels and CD4+ cell counts of youth in 14 cities. Aids, 2014, 28, 1213-1219.	2.2	11
274	Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe. Aids, 2014, 28, 1657-1664.	2.2	8
275	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	7.4	109
276	Barriers to Legal and Human Rights in Australia in the Era of HIV Treatment as Prevention. AIDS Education and Prevention, 2014, 26, 202-213.	1.1	9
277	Factors Associated with Late Initiation of Highly Active Antiretroviral Therapy among Young HIV-Positive Men and Women Aged 18 to 29 Years in Canada. Journal of the International Association of Providers of AIDS Care, 2014, 13, 56-62.	1.5	10
278	Advanced disease at enrollment in HIV care in four sub-Saharan African countries. Aids, 2014, 28, 2429-2438.	2.2	32
279	Stimulant use and HIV disease management among men in same-sex relationships. Drug and Alcohol Dependence, 2014, 139, 174-177.	3.2	18
280	The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infectious Diseases, The, 2014, 14, 40-49.	9.1	178
281	Methadone maintenance for HIV positive and HIV negative patients in Kyiv: Acceptability and treatment response. Drug and Alcohol Dependence, 2014, 137, 62-67.	3.2	18



#	ARTICLE	IF	CITATIONS
282	Adh�sion au traitement antir�troviral et �thique de la responsabilit�: devons-nous prescrire une th�rapie antir�trovirale aux personnes non adh�rentes?. �thique & Sant�, 2014, 11, 4-12.	0.1	1
283	Late Presentation and Loss to Follow-Up of Immigrants Newly Diagnosed with HIV in the HAART Era. Journal of Immigrant and Minority Health, 2014, 16, 751-755.	1.6	15
284	Dynamics of viremia in primary HIV-1 infection in Africans: Insights from analyses of host and viral correlates. Virology, 2014, 449, 254-262.	2.4	13
285	Treatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1446-1451.	1.2	0
286	Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention. Current HIV/AIDS Reports, 2014, 11, 308-316.	3.1	33
287	Editorial Commentary: Plus ca change ... Antiretroviral Therapy, HIV Prevention, and the HIV Treatment Cascade. Clinical Infectious Diseases, 2014, 58, 1012-1014.	5.8	20
288	The AIDS Pandemic in Historic Perspective. Journal of the History of Medicine and Allied Sciences, 2014, 69, 351-382.	0.8	14
290	Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997�2011. BMC Infectious Diseases, 2014, 14, 322.	2.9	17
291	A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research. BMC Medical Ethics, 2014, 15, 54.	2.4	12
292	Vulnerable Places: Prison Locations, Socioeconomic Status, and HIV Infection in Texas. Professional Geographer, 2014, 66, 653-663.	1.8	3
293	Correlates of Unstructured Antiretroviral Treatment Interruption in a Cohort of HIV-Positive Individuals in British Columbia. AIDS and Behavior, 2014, 18, 2240-2248.	2.7	11
294	Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation. Clinical Infectious Diseases, 2014, 59, S21-S27.	5.8	86
295	Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004�12: a prospective cohort study. The Lancet Global Health, 2014, 2, e209-e215.	6.3	44
296	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
297	Challenges and potential barriers to the uptake of antiretroviral-based prevention in Asia and the Pacific region. Sexual Health, 2014, 11, 126.	0.9	14
299	The key role of adherence for the effectiveness of antiretroviral-based prevention: state of the science and implications for the Asia-Pacific region. Sexual Health, 2014, 11, 155.	0.9	6
300	Life Expectancy in the Immune Recovery Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 175-181.	2.1	23
301	HIV Viral Load: A Concept Analysis and Critique. Research and Theory for Nursing Practice, 2014, 28, 204-227.	0.4	6

#	ARTICLE	IF	CITATIONS
302	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. <i>HIV Clinical Trials</i> , 2014, 15, 185-198.	2.0	6
303	Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997â€“2010. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 107-114.	2.1	14
304	Cascade of HIV care and population viral suppression in a high-burden region of Kenya. <i>Aids</i> , 2015, 29, 1557-1565.	2.2	44
305	Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia. <i>Sexual Health</i> , 2015, 12, 34.	0.9	7
306	Restricted access to antiretroviral treatment for undocumented migrants: a bottle neck to control the HIV epidemic in the EU/EEA. <i>BMC Public Health</i> , 2015, 15, 1228.	2.9	49
307	Risky sexual networks and concentrated HIV epidemics among men who have sex with men in Wenzhou, China: a respondent-driven sampling study. <i>BMC Public Health</i> , 2015, 15, 1246.	2.9	14
308	Emergence of clusters of CRF02_AG and B human immunodeficiency viral strains among men having sex with men exhibiting HIV primary infection in southeastern France. <i>Journal of Medical Virology</i> , 2015, 87, 1327-1333.	5.0	14
310	Pharmacologic Prevention of Human Immunodeficiency Virus in Women. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 284-290.	0.4	8
311	Sex Partner Meeting Places Over Time Among Newly HIV-Diagnosed Men Who Have Sex With Men in Baltimore, Maryland. <i>Sexually Transmitted Diseases</i> , 2015, 42, 549-553.	1.7	11
312	Declines in highly active antiretroviral therapy initiation at <sc>CD4</sc> cell counts $\hat{\%}\hat{\%}200\hat{\%}\hat{\%}\hat{1}/4L$ and the contribution of diagnosis of <sc>HIV</sc> at <sc>CD4</sc> cell counts $\hat{\%}\hat{\%}200\hat{\%}\hat{\%}\hat{1}/4L$ in 2.2 <sc>B</sc>ritish <sc>C</sc>olumbia, <sc>C</sc>anada. <i>HIV Medicine</i> , 2015, 16, 337-345.		10
313	Characterizing retention in HAART as a recurrent event process. <i>Aids</i> , 2015, 29, 1681-1689.	2.2	33
314	Ending AIDS and challenges for Asia. <i>Future Virology</i> , 2015, 10, 341-345.	1.8	0
315	The causal effect of opioid substitution treatment on HAART medication refill adherence. <i>Aids</i> , 2015, 29, 965-973.	2.2	40
316	Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. <i>Aids</i> , 2015, 29, 1369-1378.	2.2	17
317	A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. <i>Aids</i> , 2015, 29, 2279-2286.	2.2	23
318	Using Surveillance Data to Assess the HIV Tipping Point in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, e82-e84.	2.1	1
319	Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. <i>Patient Related Outcome Measures</i> , 2015, 6, 53.	1.2	2
320	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015, 18, 20024.	3.0	22

#	ARTICLE	IF	CITATIONS
321	Retention in HIV Care and Predictors of Attrition from Care among HIV-Infected Adults Receiving Combination Anti-Retroviral Therapy in Addis Ababa. <i>PLoS ONE</i> , 2015, 10, e0130649.	2.5	33
322	Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990–2013. <i>PLoS ONE</i> , 2015, 10, e0131353.	2.5	121
323	Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model. <i>PLoS ONE</i> , 2015, 10, e0136534.	2.5	13
325	Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. <i>Journal of Virus Eradication</i> , 2015, 1, 43-48.	0.5	39
326	Sexual Agreements and Perception of HIV Prevalence Among an Online Sample of Partnered Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2015, 44, 1813-1819.	1.9	21
328	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. <i>BMJ Open</i> , 2015, 5, e008876.	1.9	34
329	From Acute Palliation to Chronic Care: Using the Narratives of Two Gay Caregivers to Explore Experiences of Providing HIV Support Across Sociohistorical Contexts. <i>Journal of Gay and Lesbian Social Services</i> , 2015, 27, 482-501.	1.2	1
330	Rapid HIV Screening in an Urban Jail: How Testing at Exit With Linkage to Community Care Can Address Perceived Barriers. <i>Journal of Primary Prevention</i> , 2015, 36, 427-432.	1.6	8
331	Disparities in Viral Load and CD4 Count Trends Among HIV-Infected Adults in South Carolina. <i>AIDS Patient Care and STDs</i> , 2015, 29, 26-32.	2.5	33
332	Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access. <i>Clinical Infectious Diseases</i> , 2015, 60, 463-472.	5.8	27
333	Methadone Maintenance Therapy and HIV Counseling and Testing are Associated with Lower frequency of Risky Behaviors Among Injection Drug Users in China. <i>Substance Use and Misuse</i> , 2015, 50, 15-23.	1.4	21
334	Linkage and retention in care and the time to HIV viral suppression and viral rebound – New York City. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 260-267.	1.2	32
335	Design and Implementation of an External Quality Assessment Program for HIV Viral Load Measurements Using Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , 2015, 53, 964-966.	3.9	5
336	HIV Transmissions by Stage and Sex Role in Long-Term Concurrent Sexual Partnerships. <i>Acta Biotheoretica</i> , 2015, 63, 33-54.	1.5	4
337	Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012. <i>Clinical Infectious Diseases</i> , 2015, 61, 111-119.	5.8	19
338	Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. <i>AIDS and Behavior</i> , 2015, 19, 752-757.	2.7	60
339	Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV. <i>Sexually Transmitted Infections</i> , 2015, 91, 269-274.	1.9	27
340	HIV Treatment as Prevention in Jamaica and Barbados. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 82-87.	1.5	8

#	ARTICLE	IF	CITATIONS
341	Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients. <i>Viruses</i> , 2015, 7, 590-603.	3.3	10
342	Improvements in HIV Care Engagement and Viral Load Suppression Following Enrollment in a Comprehensive HIV Care Coordination Program. <i>Clinical Infectious Diseases</i> , 2015, 60, 298-310.	5.8	102
343	Significant ambivalence: perspectives of Australian HIV service providers on universal treatment-as-prevention (TasP) for serodiscordant couples. <i>Critical Public Health</i> , 2015, 25, 153-164.	2.4	10
344	High Rates of Retention and Viral Suppression in the US HIV Safety Net System: HIV Care Continuum in the Ryan White HIV/AIDS Program, 2011. <i>Clinical Infectious Diseases</i> , 2015, 60, 117-125.	5.8	98
345	Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?. <i>Journal of Addictive Diseases</i> , 2015, 34, 198-205.	1.3	13
346	Rates and Correlates of Antiretroviral Therapy Use and Virologic Suppression Among Perinatally and Behaviorally HIV-Infected Youth Linked to Care in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 169-177.	2.1	72
347	Retention in Care and Medication Adherence: Current Challenges to Antiretroviral Therapy Success. <i>Drugs</i> , 2015, 75, 445-454.	10.9	88
348	Evaluating HIV prevention strategies for populations in key affected groups: the example of Cabo Verde. <i>International Journal of Public Health</i> , 2015, 60, 457-466.	2.3	7
349	Health Care Providers' Perspectives on a Weekly Text-Messaging Intervention to Engage HIV-Positive Persons in Care (WelTel BC1). <i>AIDS and Behavior</i> , 2015, 19, 1875-1887.	2.7	30
350	The "Expanded HIV care in opioid substitution treatment" (EHOST) cluster-randomized, stepped-wedge trial: A study protocol. <i>Contemporary Clinical Trials</i> , 2015, 45, 201-209.	1.8	5
352	HIV Care Continuum Among Men Who Have Sex With Men and Persons Who Inject Drugs in India: Barriers to Successful Engagement. <i>Clinical Infectious Diseases</i> , 2015, 61, civ669.	5.8	57
353	Defeating AIDS"advancing global health. <i>Lancet, The</i> , 2015, 386, 171-218.	13.7	234
354	Impact of defined clinical population and missing data on temporal trends in <sc>HIV</sc> viral load estimation within a health care system. <i>HIV Medicine</i> , 2015, 16, 346-354.	2.2	5
355	HIV Drug Resistance Testing by High-Multiplex "Wide" Sequencing on the MiSeq Instrument. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6824-6833.	3.2	50
356	Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein" Ligand X-ray Studies. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6994-7006.	6.4	13
357	Addressing barriers to the end of AIDS by 2030. <i>Lancet HIV,the</i> , 2015, 2, e360-e361.	4.7	8
358	Qualitative Assessment of Barriers and Facilitators of Access to HIV Testing Among Men Who Have Sex with Men in China. <i>AIDS Patient Care and STDs</i> , 2015, 29, 481-489.	2.5	55
359	Systems Approach to targeted and long-acting HIV/AIDS therapy. <i>Drug Delivery and Translational Research</i> , 2015, 5, 531-539.	5.8	16

#	ARTICLE	IF	CITATIONS
361	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 58-67.	1.9	31
363	Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting. <i>Journal of the International AIDS Society</i> , 2016, 19, 20617.	3.0	12
365	Changes in self-reported HIV testing during South Africa's 2010/2011 national testing campaign: gains and shortfalls. <i>Journal of the International AIDS Society</i> , 2016, 19, 20658.	3.0	23
366	Cost-Effectiveness of the "One4All"™ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China. <i>PLoS ONE</i> , 2016, 11, e0167308.	2.5	19
367	Achieving the Goals of the National HIV/AIDS Strategy. <i>Sexually Transmitted Diseases</i> , 2016, 43, 269-276.	1.7	11
368	Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. <i>Aids</i> , 2016, 30, 925-932.	2.2	18
369	Use of a Real-Time Alert System to Identify and Re-Engage Lost-to-Care HIV Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, e52-e55.	2.1	8
370	Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012. <i>HIV Medicine</i> , 2016, 17, 694-701.	2.2	18
371	Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. <i>Addiction</i> , 2016, 111, 475-489.	3.3	33
372	Barriers to Viral Suppression Among Female Sex Workers: Role of Structural and Intimate Partner Dynamics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 83-90.	2.1	20
373	Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6826-6837.	6.4	15
374	Non-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. <i>HIV Medicine</i> , 2016, 17, 269-279.	2.2	9
375	Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. <i>HIV Medicine</i> , 2016, 17, 623-630.	2.2	4
376	Factors associated with satisfaction with community-based non-medicalized counseling and testing using HIV rapid tests among MSM in France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1240-1248.	1.2	9
377	HIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence. <i>International Journal of Epidemiology</i> , 2016, 46, dyw180.	1.9	19
378	The effect of socioeconomic disadvantage on strategies to end the AIDS epidemic. <i>Lancet Public Health</i> , 2016, 1, e6-e7.	10.0	1
379	Current status and prospects of HIV treatment. <i>Current Opinion in Virology</i> , 2016, 18, 50-56.	5.4	249
380	Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. <i>Drug and Alcohol Dependence</i> , 2016, 159, 174-180.	3.2	11

#	ARTICLE	IF	CITATIONS
381	No association between HIV status and risk of non-fatal overdose among people who inject drugs in Vancouver, Canada. <i>Addictive Behaviors</i> , 2016, 60, 8-12.	3.0	8
382	Safer Conception Methods and Counseling: Psychometric Evaluation of New Measures of Attitudes and Beliefs Among HIV Clients and Providers. <i>AIDS and Behavior</i> , 2016, 20, 1370-1381.	2.7	10
383	Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. <i>Lancet, The</i> , 2016, 388, 1103-1114.	13.7	86
384	Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 455.	2.9	17
385	Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2016, 168, 22-29.	3.2	27
386	HIV Treatment as Prevention: Implications for Health Promotion. <i>Health Promotion International</i> , 2018, 33, daw080.	1.8	1
387	HIV elimination and population viral load. <i>Lancet HIV,the</i> , 2016, 3, e507-e509.	4.7	5
388	Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response. <i>Journal of the International AIDS Society</i> , 2016, 19, 21348.	3.0	38
389	Improved Survival in HIV Treatment Programmes in Asia. <i>Antiviral Therapy</i> , 2016, 21, 517-527.	1.0	18
390	Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. <i>BMJ Open</i> , 2016, 6, e009058.	1.9	24
391	Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 590.	2.9	36
392	A longitudinal cohort study of HIV "treatment as prevention"™ in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol. <i>BMC Infectious Diseases</i> , 2016, 16, 752.	2.9	9
393	Surveillance of HIV assisted partner services using routine health information systems in Kenya. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 97.	3.0	7
394	HIV Community Viral Load and Factors Associated With Elevated Viremia Among a Community-Based Sample of Men Who Have Sex With Men in Vancouver, Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 87-95.	2.1	52
395	Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. <i>Clinical Drug Investigation</i> , 2016, 36, 377-387.	2.2	5
396	Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1448-1454.	1.2	9
397	Characteristics and consequences of medical care interruptions in HIV-infected patients in France. <i>Epidemiology and Infection</i> , 2016, 144, 2363-2370.	2.1	6
398	Empirical population and public health ethics: A review and critical analysis to advance robust empirical-normative inquiry. <i>Health (United Kingdom)</i> , 2016, 20, 274-290.	1.5	11



#	ARTICLE	IF	CITATIONS
399	Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study. <i>BMC Public Health</i> , 2016, 16, 262.	2.9	18
400	Substance use, sexual behaviour and prevention strategies of Vancouver gay and bisexual men who recently attended group sex events. <i>Culture, Health and Sexuality</i> , 2016, 18, 361-376.	1.8	23
401	Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting. <i>AIDS and Behavior</i> , 2016, 20, 2941-2949.	2.7	6
402	Programmatic and ethical challenges in the implementation of treatment-as-prevention in the context of HIV and drug-resistant tuberculosis co-infection in sub-Saharan Africa. <i>Global Public Health</i> , 2016, 11, 336-347.	2.0	0
403	Delayed entry into HIV medical care in a nationally representative sample of HIV-infected adults receiving medical care in the USA. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 325-333.	1.2	13
404	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. <i>Journal of Virology</i> , 2016, 90, 1244-1258.	3.4	13
405	ASHP Guidelines on Pharmacist Involvement in HIV Care. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 468-494.	1.0	47
406	Sex-Based Differences in Rates, Causes, and Predictors of Death Among Injection Drug Users in Vancouver, Canada. <i>American Journal of Epidemiology</i> , 2016, 183, 544-552.	3.4	22
407	HIV Risk Behaviors, Perceptions, and Testing and Preexposure Prophylaxis (PrEP) Awareness/Use in Grindr-Using Men Who Have Sex With Men in Atlanta, Georgia. <i>Journal of the Association of Nurses in AIDS Care</i> , 2016, 27, 133-142.	1.0	65
408	Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative. <i>Clinical Infectious Diseases</i> , 2016, 62, 640-647.	5.8	35
409	HIV treatment as prevention in men who have sex with men: examining the evidence. <i>Cmaj</i> , 2016, 188, 198-203.	2.0	9
410	Community viral load as an index of HIV transmission potential. <i>Lancet HIV,the</i> , 2016, 3, e152-e154.	4.7	16
411	HIV/AIDS: trends in the Middle East and North Africa region. <i>International Journal of Infectious Diseases</i> , 2016, 44, 66-73.	3.3	131
412	Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study. <i>Lancet HIV,the</i> , 2016, 3, e183-e190.	4.7	67
413	Impact of Extended Combination Antiretroviral Therapy on the Decline of HIV Prevalence in Pregnant Women in Malawi. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 172-177.	1.5	2
414	Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. <i>International Journal of Drug Policy</i> , 2016, 27, 23-35.	3.3	32
415	Structural Barriers to Antiretroviral Therapy Among Sex Workers Living with HIV: Findings of a Longitudinal Study in Vancouver, Canada. <i>AIDS and Behavior</i> , 2016, 20, 977-986.	2.7	37
416	Identifying Best Practices for Increasing Linkage to, Retention, and Re-engagement in HIV Medical Care: Findings from a Systematic Review, 1996-2014. <i>AIDS and Behavior</i> , 2016, 20, 951-966.	2.7	69

#	ARTICLE	IF	CITATIONS
417	Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 201-208.	2.8	7
418	Correlates of Perceived HIV Prevalence and Associations With HIV Testing Behavior Among Men Who Have Sex With Men in the United States. <i>American Journal of Men's Health</i> , 2016, 10, 90-99.	1.6	15
419	Getting the balance right: Scaling-up treatment and prevention. <i>Global Public Health</i> , 2017, 12, 483-497.	2.0	4
420	HIV community viral load trends in South Carolina. <i>International Journal of STD and AIDS</i> , 2017, 28, 265-276.	1.1	8
421	Evaluation of performance of human immunodeficiency virus antigen/antibody combination assays in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2017, 50, 440-447.	3.1	4
422	Does age matter? Sexual event-level analysis of age-disparate sexual partners among gay, bisexual and other men who have sex with men (GBM) in Vancouver, Canada. <i>Sexually Transmitted Infections</i> , 2017, 93, 332-341.	1.9	2
423	The Hotel Studyâ€”Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 482-492.	1.9	38
424	Sexualverhalten, STIs und HIVâ€œbertragungsrisiken bei HIVâ€positiven MSM â€” AnsÃtze fÃ¼r die Ãrztliche PrÃventionsarbeit. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 421-429.	0.8	2
425	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4267-4278.	6.4	64
426	Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virusâ€Infected People Who Use Illicit Drugs in a Canadian Setting. <i>Clinical Infectious Diseases</i> , 2017, 65, 796-802.	5.8	5
427	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2171-2183.	3.0	8
428	Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec. <i>Aids</i> , 2017, 31, 707-717.	2.2	31
429	The HIV Care Cascade and sub-analysis of those linked to but not retained in care: the experience from a tertiary HIV referral service in Dublin Ireland. <i>HIV Clinical Trials</i> , 2017, 18, 93-99.	2.0	14
430	Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy. <i>HIV Medicine</i> , 2017, 18, 711-723.	2.2	1
431	Classical and alternative macrophages have impaired function during acute and chronic HIV-1 infection. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 42-50.	0.6	14
432	Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States. <i>Clinical Trials</i> , 2017, 14, 322-332.	1.6	31
433	Moving from Public Health Failure to Opportunity. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 107-109.	1.5	1
434	Comparing viral load metrics and evaluating their use for HIV surveillance. <i>Journal of Infection</i> , 2017, 75, 169-178.	3.3	2



#	ARTICLE	IF	CITATIONS
435	Mental Health, Psychosocial Challenges and Resilience in Older Adults Living with HIV. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2017, 42, 187-203.	2.6	55
436	Sexual HIV risk among gay, bisexual and queer transgender men: findings from interviews in Vancouver, Canada. <i>Culture, Health and Sexuality</i> , 2017, 19, 1197-1209.	1.8	15
437	Number of Psychosocial Strengths Predicts Reduced HIV Sexual Risk Behaviors Above and Beyond Syndemic Problems Among Gay and Bisexual Men. <i>AIDS and Behavior</i> , 2017, 21, 3035-3046.	2.7	31
438	High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. <i>International Journal of Drug Policy</i> , 2017, 42, 63-70.	3.3	32
439	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study. <i>Lancet HIV</i> , 2017, 4, e303-e310.	4.7	31
440	Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV-positive men who have sex with men (MSM) – approaches for medical prevention. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 421-428.	0.8	11
441	Healthcare contacts among patients lost to follow-up in HIV care: review of a large regional cohort utilizing electronic health records. <i>International Journal of STD and AIDS</i> , 2017, 28, 1275-1281.	1.1	3
443	A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996–2015. <i>Journal of the International AIDS Society</i> , 2017, 20, 21941.	3.0	26
444	Association between public injecting and drug-related harm among HIV-positive people who use injection drugs in a Canadian setting: A longitudinal analysis. <i>Drug and Alcohol Dependence</i> , 2017, 180, 33-38.	3.2	19
445	Condomless Sex Among Virally Suppressed Women With HIV With Regular HIV-Serodiscordant Sexual Partners in the Era of Treatment as Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 372-381.	2.1	11
446	Awareness and understanding of HIV non-disclosure case law among people living with HIV who use illicit drugs in a Canadian setting. <i>International Journal of Drug Policy</i> , 2017, 43, 113-121.	3.3	5
447	Infecç�n por el VIH/sida: �El principio del fin de la primera gran pandemia contempor�nea?. <i>Revista Clinica Espanola</i> , 2017, 217, 468-472.	0.6	2
448	HIV/AIDS infection: The beginning of the end for today's greatest pandemic?. <i>Revista Clinica Espanola</i> , 2017, 217, 468-472.	0.5	0
449	An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors. <i>Tetrahedron Letters</i> , 2017, 58, 3230-3233.	1.4	5
450	The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis. <i>HIV Medicine</i> , 2017, 18, 580-586.	2.2	13
451	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 158-165.	2.1	8
452	Feasibility of Using HIV Care-Continuum Outcomes to Identify Geographic Areas for Targeted HIV Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, S96-S103.	2.1	14
453	Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	60

#	ARTICLE	IF	CITATIONS
454	HIV Prevention Efforts and Incidence of HIV in Uganda. <i>New England Journal of Medicine</i> , 2017, 377, 2154-2166.	27.0	163
455	Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada. <i>Antiviral Therapy</i> , 2017, 22, 403-411.	1.0	7
456	Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 439.	2.9	9
457	Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2017, 284, 20170525.	2.6	10
458	An assessment of the relationship between the World Health Organization <scp>HIV</scp> drug resistance early warning indicators and <scp>HIV</scp> drug resistance acquisition. <i>HIV Medicine</i> , 2017, 18, 342-353.	2.2	3
459	Antiretroviral Therapy Interruption Among HIV Positive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative. <i>AIDS and Behavior</i> , 2017, 21, 402-409.	2.7	24
460	Someone to count on: social support as an effect modifier of viral load suppression in a prospective cohort study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 469-480.	1.2	66
461	Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. <i>Virus Research</i> , 2017, 239, 1-9.	2.2	50
462	Principles of Management of HIV in the Industrialized World. , 2017, , 912-917.e2.		3
463	Understanding the Correlates of Attrition Associated with Antiretroviral Use and Viral Suppression Among Women Living with HIV in Canada. <i>AIDS Patient Care and STDs</i> , 2017, 31, 428-437.	2.5	7
464	Progress towards the United Nations 90â€90â€90 and 95â€95â€95 targets: the experience in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25011.	3.0	28
465	Impact of Antiretroviral Therapy on the Spread of Human Immunodeficiency Virus in Chaoyang District, Beijing, China. <i>Chinese Medical Journal</i> , 2017, 130, 32-38.	2.3	8
466	Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1724-1730.	5.8	6
467	The HIV care cascade: Japanese perspectives. <i>PLoS ONE</i> , 2017, 12, e0174360.	2.5	42
468	The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study. <i>BMC Public Health</i> , 2017, 17, 614.	2.9	21
469	Criteria for prioritization of HIV programs in Viet Nam: a discrete choice experiment. <i>BMC Health Services Research</i> , 2017, 17, 719.	2.2	7
470	Improving linkage to HIV care at low-threshold STI/HIV testing sites: An evaluation of the Immediate Staging Pilot Project in Vancouver, British Columbia. <i>Canadian Journal of Public Health</i> , 2017, 108, e79-e84.	2.3	4
471	Inseguridad alimentaria y adherencia al tratamiento antirretroviral en personas con VIH de MÃ©xico. <i>Ciencia E Saude Coletiva</i> , 2017, 22, 543-551.	0.5	1

#	ARTICLE	IF	CITATIONS
472	Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants. <i>ChemMedChem</i> , 2018, 13, 803-815.	3.2	36
473	Declining Mortality Rates in HIV-Infected People Who Inject Drugs During a Seek-and-Treat Initiative in Vancouver, Canada, 1996-2014: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 64-68.	4.0	7
474	The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013. <i>Clinical Infectious Diseases</i> , 2018, 66, 765-777.	5.8	15
475	The relationship between gastrointestinal symptom attribution, bothersomeness, and antiretroviral adherence among adults with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 997-1003.	1.2	2
476	Trends in discharges from the HIV/AIDS ward at a tertiary Canadian Hospital from 2005 to 2014. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1099-1106.	1.2	6
477	Decentralisation of Brazil's HIV/AIDS programme: intended and unintended consequences. <i>Global Public Health</i> , 2018, 13, 1725-1736.	2.0	6
478	Discordance of Self-report and Laboratory Measures of HIV Viral Load Among Young Men Who Have Sex with Men and Transgender Women in Chicago: Implications for Epidemiology, Care, and Prevention. <i>AIDS and Behavior</i> , 2018, 22, 2360-2367.	2.7	21
479	A Pilot Study to Increase the Efficiency of HIV Outreach Testing Through the Use of Timely and Geolocated HIV Viral Load Surveillance Data. <i>Sexually Transmitted Diseases</i> , 2018, 45, 207-211.	1.7	3
480	CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection. <i>Human Gene Therapy</i> , 2018, 29, 1264-1276.	2.7	33
481	Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. <i>Drug and Alcohol Dependence</i> , 2018, 182, 86-92.	3.2	74
482	Rethinking prevention: Shifting conceptualizations of evidence and intervention in South Africa's AIDS epidemic. <i>BioSocieties</i> , 2018, 13, 148-169.	1.3	5
483	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. <i>Lancet HIV</i> , 2018, 5, e116-e125.	4.7	187
484	Longitudinal Trends in the Prevalence of Detectable HIV Viremia: Population-Based Evidence From Rural KwaZulu-Natal, South Africa. <i>Clinical Infectious Diseases</i> , 2018, 66, 1254-1260.	5.8	12
485	The Clinic Environment as a Form of Social Support for Adolescents and Young Adults Living with HIV. <i>AIDS Patient Care and STDs</i> , 2018, 32, 208-213.	2.5	13
486	News of Biomedical Advances in HIV: Relationship to Treatment Optimism and Expected Risk Behavior in US MSM. <i>AIDS and Behavior</i> , 2018, 22, 367-378.	2.7	5
487	Perceived HIV Prevalence Accuracy and Sexual Risk Behavior Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2018, 22, 1849-1857.	2.7	8
488	Seroadaptive Strategies of Vancouver Gay and Bisexual Men in a Treatment as Prevention Environment. <i>Journal of Homosexuality</i> , 2018, 65, 524-539.	2.0	13
489	Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS. <i>AIDS and Behavior</i> , 2018, 22, 234-244.	2.7	3

#	ARTICLE	IF	CITATIONS
490	Readiness for Antiretroviral Therapy: Implications for Linking HIV-Infected Individuals to Care and Treatment. <i>AIDS and Behavior</i> , 2018, 22, 691-700.	2.7	16
491	Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 8-16.	2.1	34
492	Epidemiology and Prevention of HIV Infection in Children and Adolescents. , 2018, , 659-665.e4.		0
493	High HIV-1 RNA Among Newly Diagnosed People in Botswana. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 300-306.	1.1	2
494	Stumbling Blocks at the Clinic: Experiences of Seeking HIV Treatment and Care in South Africa. <i>AIDS and Behavior</i> , 2018, 22, 765-773.	2.7	38
495	Measures of human immunodeficiency virus (HIV) community viral load and HIV incidence among people who inject drugs. <i>Annals of Epidemiology</i> , 2018, 28, 8-12.	1.9	1
496	HIV Acquisition and Transmission Potential Among African American Men Who Have Sex with Men and Women in Three U.S. Cities. <i>Archives of Sexual Behavior</i> , 2018, 47, 183-194.	1.9	15
497	HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen. <i>Journal of Clinical Virology</i> , 2018, 109, 45-49.	3.1	6
498	Viral load testing and the use of test results for clinical decision making for HIV treatment in Cameroon: An insight into the clinic-laboratory interface. <i>PLoS ONE</i> , 2018, 13, e0198686.	2.5	23
499	Changes of sexual risk behaviors and sexual connections among HIV-positive men who have sex with men along their HIV care continuum. <i>PLoS ONE</i> , 2018, 13, e0209008.	2.5	12
500	Modelling the dynamics of population viral load measures under HIV treatment as prevention. <i>Infectious Disease Modelling</i> , 2018, 3, 160-170.	1.9	4
501	A primer on multiscale modelling of infectious disease systems. <i>Infectious Disease Modelling</i> , 2018, 3, 176-191.	1.9	24
502	Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9722-9737.	6.4	24
503	Reaching the WHO target of testing persons in jails in prisons will need diverse efforts and resources. <i>PLoS ONE</i> , 2018, 13, e0202985.	2.5	3
504	Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. <i>European Journal of Medicinal Chemistry</i> , 2018, 160, 171-182.	5.5	4
505	Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial. <i>Trials</i> , 2018, 19, 396.	1.6	6
506	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.0	22
507	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4561-4577.	6.4	31

#	ARTICLE	IF	CITATIONS
509	Medication adherence to antiretroviral therapy among newly treated people living with HIV. <i>BMC Public Health</i> , 2018, 18, 825.	2.9	51
510	HIV. <i>Lancet, The</i> , 2018, 392, 685-697.	13.7	219
511	Sexual Risk Behaviors of Patients with HIV/AIDS over the Course of Antiretroviral Treatment in Northern Vietnam. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1106.	2.6	17
512	Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings. <i>Viruses</i> , 2018, 10, 10.	3.3	29
513	Condom use in combination with ART can reduce HIV incidence and mortality of PLWHA among MSM: a study from Beijing, China. <i>BMC Infectious Diseases</i> , 2018, 18, 124.	2.9	12
514	Reduction in HIV community viral loads following the implementation of a "Treatment as Prevention" strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China. <i>BMC Infectious Diseases</i> , 2018, 18, 62.	2.9	7
515	HIV viral suppression in Oman: Encouraging progress toward achieving the United Nations "third 90"™. <i>International Journal of Infectious Diseases</i> , 2018, 71, 94-99.	3.3	7
516	Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. <i>PLoS ONE</i> , 2018, 13, e0190487.	2.5	100
517	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	3.1	25
518	Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009-2014. <i>AIDS and Behavior</i> , 2019, 23, 3452-3459.	2.7	42
519	Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3305-3314.	3.0	6
520	Hiring, training, and supporting Peer Research Associates: Operationalizing community-based research principles within epidemiological studies by, with, and for women living with HIV. <i>Harm Reduction Journal</i> , 2019, 16, 47.	3.2	44
521	A systematic review of the geospatial barriers to antiretroviral initiation, adherence and viral suppression among people living with HIV. <i>Sexual Health</i> , 2019, 16, 1.	0.9	9
522	Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2019, 366, l4179.	2.3	21
523	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. <i>EBioMedicine</i> , 2019, 48, 405-413.	6.1	8
524	The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy. <i>International Journal of Genomics</i> , 2019, 2019, 1-14.	1.6	5
525	Correlates of same-sex behavior disclosure to health care providers among Black MSM in the United States: implications for HIV prevention. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1011-1018.	1.2	7
526	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 89-93.	2.1	41

#	ARTICLE	IF	CITATIONS
527	Cost-effectiveness of HIV care coordination scale-up among persons at high risk for sub-optimal HIV care outcomes. PLoS ONE, 2019, 14, e0215965.	2.5	7
528	Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2019, 37, 361-366.	0.3	0
529	Population uptake and effectiveness of test-and-treat antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological cross-national analysis. HIV Medicine, 2019, 20, 501-512.	2.2	10
530	Evaluation of a Computer-Based HIV Education Program for Adults Living with HIV. AIDS and Behavior, 2019, 23, 3152-3164.	2.7	7
531	Primary health care: an opportunity for early identification of people living with undiagnosed HIV infection. HIV Medicine, 2019, 20, 404-417.	2.2	6
532	Retention in care and mortality trends among patients receiving comprehensive care for HIV infection: a retrospective cohort study. CMAJ Open, 2019, 7, E236-E245.	2.4	4
533	HIV testing and HIV knowledge among men who have sex with men in Natal, Northeast Brazil. Brazilian Journal of Infectious Diseases, 2019, 23, 2-7.	0.6	8
534	Women, incarceration and HIV. Aids, 2019, 33, 101-111.	2.2	25
535	Is reaching 90-90-90 enough to end AIDS? Lessons from Amsterdam. Current Opinion in HIV and AIDS, 2019, 14, 455-463.	3.8	10
536	Exploring HIV-1 Transmission Dynamics by Combining Phylogenetic Analysis and Infection Timing. Viruses, 2019, 11, 1096.	3.3	9
537	How Big Data Science Can Improve Linkage and Retention in Care. Infectious Disease Clinics of North America, 2019, 33, 807-815.	5.1	7
538	Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs. Lancet HIV, 2019, 6, e128-e136.	4.7	27
539	The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. Value in Health, 2019, 22, 194-202.	0.3	20
540	Pérdidas de seguimiento de personas con infección por el VIH en la cohorte española VACH en el periodo 2013-2014: importancia de los factores sociodemográficos. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 361-366.	0.5	6
541	Awareness and Understanding of HIV Non-disclosure Case Law and the Role of Healthcare Providers in Discussions About the Criminalization of HIV Non-disclosure Among Women Living with HIV in Canada. AIDS and Behavior, 2020, 24, 95-113.	2.7	13
542	The cascade of HIV care in Oman, 2015-2018: A population-based study from the Middle East. International Journal of Infectious Diseases, 2020, 90, 28-34.	3.3	12
543	Human Immunodeficiency Virus Infection. , 2020, , 232-266.		3
544	Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants. European Journal of Medicinal Chemistry, 2020, 185, 111866.	5.5	21



#	ARTICLE	IF	CITATIONS
545	Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 263-270.	2.1	33
546	Material security and adherence to antiretroviral therapy among HIV-positive people who use illicit drugs. <i>Aids</i> , 2020, 34, 1037-1045.	2.2	3
547	Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. <i>Journal of Infectious Diseases</i> , 2020, 222, S322-S334.	4.0	10
548	Development of a global index measuring national policy commitments to HIV prevention and treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 84, 102877.	3.3	3
549	Preventing HIV outbreaks among people who inject drugs in the United States: plus Ã change, plus Ã mÃme chose. <i>Aids</i> , 2020, 34, 1997-2005.	2.2	18
550	Post-exposure prophylaxis for Blood-Borne Viral (BBV) Infections. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 83-91.	1.1	3
551	Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable=Untransmittable Messaging Among Sexual Minority Men Living with HIV. <i>AIDS Patient Care and STDs</i> , 2020, 34, 444-451.	2.5	39
552	Cohort profile: the STOP HIV/AIDS Program Evaluation (SHAPE) study in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e033649.	1.9	5
553	Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. <i>AIDS and Behavior</i> , 2020, 24, 3473-3481.	2.7	27
554	A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. <i>Journal of Biomedical Informatics</i> , 2020, 107, 103475.	4.3	5
555	Perspectives of pregnant women, family members and health professionals on medication adherence in Nigeria. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1295-1303.	1.2	1
556	Implementation opportunities and challenges identified by key stakeholders in scaling up HIV Treatment as Prevention in British Columbia, Canada: a qualitative study. <i>Implementation Science Communications</i> , 2020, 1, 54.	2.2	4
557	Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1 ligand to enhance binding with S1 subsite. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115623.	3.0	3
558	Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. <i>BMC Public Health</i> , 2020, 20, 89.	2.9	2
559	Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016. <i>Clinical Infectious Diseases</i> , 2020, 71, 3144-3151.	5.8	43
560	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25455.	3.0	96
561	Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1965-1972.	2.8	6
562	Human immunodeficiency virus prevention strategies in China. <i>Chinese Medical Journal</i> , 2020, 133, 318-325.	2.3	8

#	ARTICLE	IF	CITATIONS
563	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4867-4879.	6.4	19
564	Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1196-1204.	2.8	7
565	Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 <sup>2</sup> ligands. <i>Future Medicinal Chemistry</i> , 2020, 12, 775-794.	2.3	6
566	Earlier treatment initiation is associated with a decreased number of HIV-1 subtype A1 transmissions in Greece. <i>Sexually Transmitted Infections</i> , 2021, 97, 232-237.	1.9	2
567	Evidence for HIV transmission across key populations: a longitudinal analysis of HIV and AIDS rates among Black people who inject drugs and Black heterosexuals in 84 large U.S. metropolitan areas, 2008-2016. <i>Annals of Epidemiology</i> , 2021, 55, 69-77.e5.	1.9	5
568	HIV viral load trajectories of women living with HIV in Metro Vancouver, Canada. <i>International Journal of STD and AIDS</i> , 2021, 32, 322-330.	1.1	6
569	Primary HIV-1 infection in users of pre-exposure prophylaxis. <i>Lancet HIV</i> , 2021, 8, e166-e174.	4.7	23
570	The opioid crisis and HIV in the USA: deadly synergies. <i>Lancet, The</i> , 2021, 397, 1139-1150.	13.7	68
571	What gaps remain in the HIV cascade of care? Results of a population-based survey in Nsanje District, Malawi. <i>PLoS ONE</i> , 2021, 16, e0248410.	2.5	6
572	Adherence to antiretroviral therapy among HIV positive men who inject drugs in Pakistan. <i>International Journal of Drug Policy</i> , 2021, 96, 103281.	3.3	5
573	Immunogenetic determinants of heterosexual HIV-1 transmission: key findings and lessons from two distinct African cohorts. <i>Genes and Immunity</i> , 2021, 22, 65-74.	4.1	0
574	The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression. <i>Clinical Infectious Diseases</i> , 2021, 73, 1951-1956.	5.8	12
575	Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study. <i>Lancet HIV</i> , 2021, 8, e440-e448.	4.7	11
576	Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113450.	5.5	11
577	Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113498.	5.5	10
578	Population Viral Load, Viremia, and Recent HIV-1 Infections: Findings From Population-Based HIV Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, S81-S88.	2.1	7
579	Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 570-579.	6.0	4
580	Incidence and Predictors of Hypertension Among HIV Patients Receiving ART at Public Health Facilities, Northwest Ethiopia: A One-Year Multicenter Prospective Follow-Up Study. <i>HIV/AIDS - Research and Palliative Care</i> , 2021, Volume 13, 889-901.	0.8	8



#	ARTICLE	IF	CITATIONS
581	Multilevel Analysis of Individual and Neighborhood Characteristics Associated with Viral Suppression Among Adults with HIV in Rio de Janeiro, Brazil. <i>AIDS and Behavior</i> , 2022, 26, 947-962.	2.7	4
582	Population HIV viral load metrics for community health. <i>Lancet HIV</i> , 2021, 8, e523-e524.	4.7	2
583	Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity. <i>ELife</i> , 2021, 10, .	6.0	27
584	Bibliometric analysis of the top 100 cited articles on HIV/AIDS. <i>Annals of Infection</i> , 0, 5, 6-6.	0.0	2
585	Advances, Promises, and Challenges in HIV Prevention. , 2014, , 3-28.		1
586	Presumptive Criminals: U.S. Criminal Law and HIV-Related Aggravated Assaults. , 2014, , 363-385.		1
587	Mutational Immune Escape in HIV-1 Infection. , 2015, , 667-706.		1
588	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	3.1	6
589	Moving towards HIV treatment as prevention. <i>Microbiology Australia</i> , 2014, 35, 88.	0.4	1
590	Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?. <i>Sexual Health</i> , 2013, 10, 166.	0.9	13
591	Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa503.	0.9	24
592	HIV-1 treatment as prevention: the good, the bad, and the challenges. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 1.	3.8	66
593	Ending an HIV epidemic among persons who inject drugs in a middle-income country: extremely low HIV incidence among persons who inject drugs in Hai Phong, Viet Nam. <i>Aids</i> , 2020, 34, 2305-2311.	2.2	19
595	The Evolving Landscape of the Economics of HIV Treatment and Prevention. <i>PLoS Medicine</i> , 2012, 9, e1001174.	8.4	8
596	Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention. <i>PLoS Medicine</i> , 2015, 12, e1001874.	8.4	52
597	A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002292.	8.4	95
598	Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013. <i>PLoS ONE</i> , 2010, 5, e15677.	2.5	37
599	Tracking the Evolution of HIV/AIDS in China from 1989 to 2009 to Inform Future Prevention and Control Efforts. <i>PLoS ONE</i> , 2011, 6, e25671.	2.5	36

#	ARTICLE	IF	CITATIONS
600	Morbidity and Risk of Subsequent Diagnosis of HIV: A Population Based Case Control Study Identifying Indicator Diseases for HIV Infection. PLoS ONE, 2012, 7, e32538.	2.5	25
601	Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLoS ONE, 2012, 7, e38335.	2.5	120
602	Disparities in the Burden of HIV/AIDS in Canada. PLoS ONE, 2012, 7, e47260.	2.5	36
603	Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. PLoS ONE, 2012, 7, e47859.	2.5	21
604	Measuring Population Transmission Risk for HIV: An Alternative Metric of Exposure Risk in Men Who Have Sex with Men (MSM) in the US. PLoS ONE, 2012, 7, e53284.	2.5	60
605	Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada. PLoS ONE, 2013, 8, e54416.	2.5	46
606	Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. PLoS ONE, 2013, 8, e55312.	2.5	197
607	Changing Risk Behaviours and the HIV Epidemic: A Mathematical Analysis in the Context of Treatment as Prevention. PLoS ONE, 2013, 8, e62321.	2.5	6
608	HIV-1 Diversity and Drug Resistance Mutations among People Seeking HIV Diagnosis in Voluntary Counseling and Testing Sites in Rio de Janeiro, Brazil. PLoS ONE, 2014, 9, e87622.	2.5	22
609	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention" Experience in a Canadian Setting. PLoS ONE, 2014, 9, e87872.	2.5	272
610	Risk Factors for Delayed Entrance into Care after Diagnosis among Patients with Late-Stage HIV Disease in Southern Vietnam. PLoS ONE, 2014, 9, e108939.	2.5	27
611	A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Quebec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load. PLoS ONE, 2014, 9, e109420.	2.5	14
612	Attrition through Multiple Stages of Pre-Treatment and ART HIV Care in South Africa. PLoS ONE, 2014, 9, e110252.	2.5	55
613	HIV Viral Load Trends in Six Eastern Caribbean Countries Utilizing a Regional Laboratory Referral Service: Implications for Treatment as Prevention. PLoS ONE, 2015, 10, e0125435.	2.5	4
614	Lack of Effectiveness of Antiretroviral Therapy in Preventing HIV Infection in Serodiscordant Couples in Uganda: An Observational Study. PLoS ONE, 2015, 10, e0132182.	2.5	14
615	The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope. PLoS ONE, 2016, 11, e0149467.	2.5	6
616	Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey. PLoS ONE, 2016, 11, e0154318.	2.5	39
617	Retention in Care among HIV-Infected Adults in Ethiopia, 2005-2011: A Mixed-Methods Study. PLoS ONE, 2016, 11, e0156619.	2.5	29

#	ARTICLE	IF	CITATIONS
618	Cigarette smoking is associated with high HIV viral load among adults presenting for antiretroviral therapy in Vietnam. PLoS ONE, 2017, 12, e0173534.	2.5	22
619	Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS ONE, 2018, 13, e0192077.	2.5	19
620	Global Mortality and Morbidity of HIV/AIDS. , 2017, , 29-44.		13
621	Design, Synthesis, Docking Studies and Biological Activities Novel 2,3- Diaryl-4-Quinazolinone Derivatives as Anti-HIV-1 Agents. Current HIV Research, 2019, 17, 214-222.	0.5	16
622	Assessing Implicit Cognition Among Patients Lost to Follow-up for HIV Care: A Preliminary Study. Open AIDS Journal, 2016, 10, 83-92.	0.5	4
623	Time From HIV Diagnosis to Viral Suppression: Survival Analysis of Statewide Surveillance Data in Alabama, 2012 to 2014. JMIR Public Health and Surveillance, 2020, 6, e17217.	2.6	2
624	Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study. Journal of Medical Internet Research, 2017, 19, e190.	4.3	26
625	HIV Trends in the United States: Diagnoses and Estimated Incidence. JMIR Public Health and Surveillance, 2017, 3, e8.	2.6	92
626	A Dyadic Behavioral Intervention to Optimize Same Sex Male Couplesâ€™ Engagement Across the HIV Care Continuum: Development of and Protocol for an Innovative Couples-based Approach (Partner Steps). JMIR Research Protocols, 2016, 5, e168.	1.0	33
627	HIV and HCV in U.S. Prisons and Jails: The Correctional Facility as a Bellwether Over Time for the Communityâ€™s Infections. AIDS Reviews, 2017, 19, .	1.0	44
628	Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection, Denmark, 1998 to 2016. Eurosurveillance, 2019, 24, .	7.0	4
629	Antiretroviral therapy for prevention of HIV transmission: implications for Europe. Eurosurveillance, 2013, 18, 20647.	7.0	15
630	A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. Eurosurveillance, 2014, 19, .	7.0	12
631	AMMI Canada position statement: The use of early antiretroviral therapy in HIV-infected persons. Jammi, 2017, 1, 1-11.	0.5	2
632	Degree of Disease Progression in Homeless HIV/AIDS Patients during the First Medical Visit. Infection and Chemotherapy, 2011, 43, 198.	2.3	2
633	When to start ART in adults? The results of HPTN 052 move us closer to a test-and-treat policy. Southern African Journal of HIV Medicine, 2011, 12, 9.	0.9	3
634	HIV serodiscordant relationships in India: Translating science to practice. Indian Journal of Medical Research, 2011, 134, 904.	1.0	16
635	Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call. Journal of AIDS & Clinical Research, 2012, 01, .	0.5	7

#	ARTICLE	IF	CITATIONS
636	The Future of Melanoma Therapy is the Combination Approach. Journal of Molecular Biomarkers & Diagnosis, 2011, 02, .	0.4	2
637	World Health Organization guidelines should not change the CD4 count threshold for antiretroviral therapy initiation. Southern African Journal of HIV Medicine, 2013, 14, .	0.9	2
640	A Simple Model for a Complex Issue. International Journal of Healthcare Delivery Reform Initiatives, 2011, 3, 60-74.	0.0	2
641	HIV Prevention in Papua New Guinea: Is It Working or Not?. World Journal of AIDS, 2012, 02, 117-121.	0.3	1
642	HIV Epidemic. , 2013, , 3-46.		1
643	Un d'Ã©pistage Ã©largi et une prise en charge thÃ©rapeutique prÃ©coce. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1157-1175.	0.0	0
644	Community Viral Load. , 2014, , 1-10.		0
645	Test and Treat in Washington, DC: Evaluating the Costs and Benefits of a Comprehensive Strategy to Fight HIV/AIDS. Policy Perspectives, 0, 21, 7.	0.0	0
646	Beyond the bedside: A review of translational medicine in global health. World Journal of Translational Medicine, 2015, 4, 1.	3.5	0
647	Modeling the Global Public Health Determinants of HIV/AIDS-Related Deaths. SSRN Electronic Journal, 0, , .	0.4	0
648	Optimising Antiretroviral Therapy Via Pharmacokinetics. , 2016, , 265-284.		0
649	Comprehensive Prevention with HIV Positive Gay Men. , 2017, , 121-149.		0
650	HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials. , 2017, , 479-498.		0
651	Optimising Antiretroviral Therapy Via Pharmacokinetics. , 2017, , 265-284.		0
652	Community Viral Load. , 2018, , 345-352.		0
654	Health Care Provider Utilization and Cost of an mHealth Intervention in Vulnerable People Living With HIV in Vancouver, Canada: Prospective Study. JMIR MHealth and UHealth, 2018, 6, e152.	3.7	9
660	The Bio/Necropolitics of ACTG 076: Lessons from Pregnant Women of Colour Living with HIV for Treatment for Prevention in the Twenty-first Century. Somatechnics, 2020, 10, 233-253.	0.7	0
661	No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study. Current HIV Research, 2020, 18, 362-372.	0.5	0

#	ARTICLE	IF	CITATIONS
662	Switch from 200 to 350 CD4 baseline count: what it means to HIV care and treatment programs in Kenya. <i>Pan African Medical Journal</i> , 2012, 12, 80.	0.8	4
664	Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. <i>Rhode Island Medical Journal</i> (2013), 2014, 98, 26-30.	0.2	6
665	Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. <i>Journal of Virus Eradication</i> , 2015, 1, 43-8.	0.5	34
666	Treatment as prevention: toward an AIDS-free generation. <i>Topics in Antiviral Medicine</i> , 2013, 21, 110-4.	0.1	20
667	Virologic and immunologic responses of patients on highly active antiretroviral therapy in a rural community health centre in Limpopo, South Africa: A retrospective study. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 818.	0.9	2
668	Provider preferences for delivery of HIV care coordination services: results from a discrete choice experiment. <i>Journal of the International AIDS Society</i> , 2022, 25, e25887.	3.0	2
669	Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C4-Substituted Tricyclic Hexahydrofurofuran Derivatives as P2 Ligands. <i>ChemMedChem</i> , 2022, 17, .	3.2	2
670	Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114251.	5.5	1
671	HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys. <i>PLoS ONE</i> , 2021, 16, e0260892.	2.5	9
672	Pocket-to-Lead: Structure-Based <i>De Novo</i> Design of Novel Non-peptidic HIV-1 Protease Inhibitors Using the Ligand Binding Pocket as a Template. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6157-6170.	6.4	6
673	Human immunodeficiency virus infection. , 0, , 360-370.		0
676	A Comparative Analysis of Different HIV Viral Load Suppression Definitions Among Clients Receiving Care in the Miami-Dade Ryan White HIV/AIDS Program. <i>AIDS and Behavior</i> , 2022, , 1.	2.7	0
677	A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 64, 116760.	3.0	2
679	A qualitative assessment of barriers and facilitators to antiretroviral therapy adherence among human immunodeficiency virus patients in Jordan. <i>Electronic Journal of General Medicine</i> , 2022, 19, em395.	0.7	1
680	Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. <i>EClinicalMedicine</i> , 2022, 52, 101600.	7.1	10
681	HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2022, 18, e1010613.	4.7	6
682	Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14178.	4.1	0
683	Epidemiology and Prevention of HIV Infection in Infants, Children, and Adolescents. , 2023, , 681-684.e4.		0

#	ARTICLE	IF	CITATIONS
684	Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2023, 246, 114981.	5.5	3
685	Biomedical Strategies for Human Immunodeficiency Virus (HIV) Prevention? A New Paradigm. <i>Annals of the Academy of Medicine, Singapore</i> , 2012, 41, 595-601.	0.4	7
686	Exploring the causes of preexposure prophylaxis of HIV failure—future developments for overcoming the same—a mini review. <i>Journal of Human Virology &amp; Retrovirology</i> , 2019, 7, 1-5.	0.2	1
687	Towards designing of a potential new HIV-1 protease inhibitor using QSAR study in combination with Molecular docking and Molecular dynamics simulations. <i>PLoS ONE</i> , 2023, 18, e0284539.	2.5	4
688	Laboratory diagnosis of HIV: a contemporary overview in the Australian context. <i>Pathology</i> , 2023, 55, 610-620.	0.6	1
689	A phenoxy-bridged trinuclear Ni(II) complex: synthesis, structural elucidation and molecular docking with viral proteins. <i>New Journal of Chemistry</i> , 2023, 47, 10424-10445.	2.8	1
690	The epidemiology of HIV population viral load in twelve sub-Saharan African countries. <i>PLoS ONE</i> , 2023, 18, e0275560.	2.5	0
691	Study protocol for data to suppression (D2S): a cluster-randomised, stepped-wedge effectiveness trial of a reporting and capacity-building intervention to improve HIV viral suppression in housing and behavioural health programmes in New York City. <i>BMJ Open</i> , 2023, 13, e076716.	1.9	0
692	Exposure to Biological Fluids in Dental Practice—Narrative Review on Appropriate Risk Assessment to Guide Post-Exposure Management. <i>Pathogens</i> , 2023, 12, 968.	2.8	0
693	It's all about connection: Determinants of social support and the influence on HIV treatment interruptions among people living with HIV in British Columbia, Canada. <i>BMC Public Health</i> , 2023, 23, .	2.9	0
694	Self-Emulsifying Drug Delivery System for Enhanced Oral Delivery of Tenofovir: Formulation, Physicochemical Characterization, and Bioavailability Assessment. <i>ACS Omega</i> , 0, , .	3.5	0